Advanced search
Publication Cover
Emerging Therapeutic Targets Volume 4, 2000 - Issue 5
Journal homepage
68
Views
57
CrossRef citations to date
0
Altmetric
Review

Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects

Mark D Sternlicht Department of Anatomy, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA. [email protected]
&
Gabriele Bergers Department of Biochemistry and Biophysics, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA. [email protected]
Pages 609-633 | Published online: 25 Feb 2005

Bibliography

  • STERNLICHT MD, WERB Z: ECM proteinases. In: Guidebook to the Extracellular Matrix, Anchor and Adhesion Proteins. Kreis T, Vale R (Eds.), Oxford University Press, Oxford, UK (1999):503–562.
  • •An excellent review of MMP structure and function.
  • BERGERS G, COUSSENS LM: Extrinsic regulators of epithelial tumor progression: met alloproteinases. Curr. Opin. Genet. Dev. (2000) 10 (1) : 120–127.
  • WERB Z: ECM and cell surface proteolysis: regulating cellular ecology. Cell (1997) 91 (4):439–442.
  • GIAMBERNARDI TA, GRANT GM, TAYLOR GP et al.: Overview of matrix met alloproteinase expression in cultured human cells. MatrixBiol (1998) 16(8) :483–496.
  • COUSSENS LM, WERB Z: Matrix met alloproteinases and the development of cancer. Chem. Biol. (1996) 3 (10:895–904.
  • MCKERROW JH, BHARGAVA V, HANSELL E et al.: Afunctional proteomics screen of proteases in colorectal carcinoma. Mol. Med. (2000) 6(5):450–460.
  • •An excellent study indicating that although most MMPs are transcribed and secreted by stromal cells, the proteins themselves are bound by the tumour cells, thus leading to seemingly contradictory results by in situ hybridisation and immunohistochemistry.
  • BERGERS G, JAVAHERIAN K, LO KM, FOLKMAN J, HANAHAN D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (1999) 284 (5415):808–812.
  • ••The first study to test the influence of MMPI in a stage-dependent manner.
  • STERNLICHT MD, LOCHTER A, SYMPSON CJ et al.: The stromal proteinase MMP-3/stromelysin-1 promotes mammary carcinogenesis. Cell (1999) 98(2)137–146.
  • ••The first study to show that an MMP can promote sponta-neous neoplastic changes.
  • STERNLICHT MD, BISSELL MJ, WERB Z: The matrix met alloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene (2000) 19 (8):1102–1113.
  • MASSON R, LEFEBVRE O, NOEL A et al.: In vivo evidence that the stromelysin-3 met alloproteinase contributes in a paracrine manner to epithelial cell malignancy. J. Cell Biol. (1998) 140(6):1535–1541.
  • WILSON CL, HEPPNER KJ, LABOSKY PA, HOGAN BL, MATRISIAN LM: Intestinal tumorigenesis is suppressed in mice lacking the met alloproteinase matrilysin. Proc. Natl. Acad. ScL USA (1997) 94 (4) :1402–1407.
  • RUDOLPH-OWEN LA, CHAN R, MULLER WJ, MATRISIANLM: The matrix met alloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res. (1998) 58 (23):5500–5506.
  • D'ARMIENTO J, DICOLANDREA T, DALAL SS et al.: Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis. Mol. Cell. Biol. (1995) 15 (10):5732–5739.
  • ••The first study to show that an MMP can promotecarcinogenesis.
  • MARTIN DC, ROTHER U, SANCHEZ-SWEATMAN OH, ORR FW, KHOKHA R: Inhibition of SV40 T antigen-induced hep ato cellular carcinoma in TIMP-1 tr an sgen ic mice. Oncogene (1996) 13(3):569–576.
  • MARTIN DC, SANCHEZ-SWEATMAN OH, HO AT et al.: Transgenic TIMP-1 inhibits simian virus 40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis. Lab. Invest. (1999) 79(2):225–234.
  • LOCHTER A, GALOSY S, MUSCHLER J et al.: Matrix met alloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol. (1997) 139 (7) :1861–1872.
  • STOCKER W, GRAMS F, BAUMANN U et al.: The metzincins-topological and sequential relations between the astacins, adamalysins, serralysins and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Science (1995) 4 (5):823–840.
  • BLACK RA, WHITE JM: ADAIVIs: focus on the protease domain. Curr. Opin. Cell Biol. (1998) 10(5):654–659.
  • •An excellent review of the ADAMs.
  • TANG BL, HONG W: ADAMTS: a novel family of proteases with an ADAM protease domain and thrombospondin 1 repeats. FEBS Lett. (1999) 445 (2-3):223–225.
  • IRUELA-ARISPE ML, VAZQUEZ F, ORTEGA MA: Antiangio-genic domains shared by thrombospondins and met allospondins, a new family of angiogenic inhibi-tors. Ann. NY Acad. Sci. (1999) 886:58–66.
  • BEIN K, SIMONS M: Thrombospondin Type 1 repeats interact with matrix met alloproteinase 2: regulation of met alloproteinase activity. J Biol. Chem. (2000) (In Press).
  • NAGASE H, WOESSNER JF: Matrix met alloproteinases. Biol. Chem. (1999) 274(30:21491–21494.
  • •An excellent review of MMP structure and function.
  • LLANO E, PENDAS AM, FREIJE JP et al.: Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overex-pressed in brain tumors. Cancer Res. (1999) 59(102570–2576.
  • VALESCO G, PENDAS AM, FUEYO A et al.: Cloning and characterization of human MMP-23, a new matrix met alloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J. Biol. Chem. (1999) 274 (8):4570–4576.
  • PARK HI, NI J, GERKEMA FE et al.: Identification andcharacterization of human endometase (matrix met alloproteinase-26) from endometrial tumor. J Chem. (2000) 275(27):20540–20544.
  • STERNLICHT MD, COUSSENS LM, VU TH, WERB Z: Biology and regulation of the matrix met alloprote-inases. In: Matrix M et alloproteinase Inhibitors in Cancer Therapy. Clendeninn NJ, Appelt K (Eds.), Humana Press, Totowa, New Jersey, USA (2000):1–37.
  • GURURAJAN R, GRENET J, LAHTI JM, KIDD VJ: Isolation and characterization of two novel met alloproteinase genes linked to the CdC2L locus on human chromo-some 1p36.3. Genomics (1998) 52:101–106.
  • VAN WART HE, BIRKEDAL-HANSEN H: The cysteine switch: a principle of regulation of met alloproteinase activity with potential applicability to the entire matrix met alloproteinase gene family. Proc. Natl. Acad. Sci. USA (1990) 87(14):5578–5582.
  • PEI D, WEISS SJ: Furin-dependent intracellular activa-tion of the human stromelysin-3 zymogen. Nature (1995) 375 (6528):244–247.
  • STRONGIN AY, COLLIER I, BANNIKOV G et al.: Mechanism of cell surface activation of 72-kDa Type W collagenase. Isolation of the activated form of the membrane met alloprotease. J. Biol. Chem. (1995) 270(105331–5338.
  • ZUCKER S, DREWS M, CONNER C et al.: Tissue inhibitor of met alloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane Type 1-matrix met alloproteinase 1 (MT1-MMP). J. Biol. Chem. (1998) 273(2):1216–1222.
  • OKUMURA Y, SATO H, SEIKI M, KIDO H: Proteolytic activation of the precursor of membrane Type 1 matrix met alloproteinase by human plasmin. A possible cell surface activator. FEBS Lett. (1997) 402(2-3):181–184.
  • BROOKS PC, STROMBLAD S, SANDERS LC et al.: localiza-tion of matrix met alloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell (1996) 85(5):683–693.
  • •The first study suggesting that an MMP:integrin complex promotes angiogenesis.
  • YU Q, STAMENKOVIC I: Localization of matrix met allo-proteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. (1999) 13 (1):35–48.
  • MORINI M, MOTTOLESE M, FERRARI N et al.: The alpha3beta1 integrin is associated with mammary carcinoma cell metastasis, invasion and gelatinase B (mmp-9) activity. Int. J. Cancer (2000) 87 (3):336–342.
  • TOTH M, SADO Y, NINOMIYA Y, FRIDMAN R: Biosyn-thesis of alpha2 (IV) and alpha1 (IV) chains of collagen IV and interactions with matrix met alloproteinase-9. Cell. Physic)]. (1999) 180(1):131–139.
  • LUKASHEV ME, WERB Z: ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol. (1998) 8:437–441.
  • LIU Z, ZHOU X, SHAPIRO SD et al.: The serpin, a1-proteinase inhibitor, is a critical substrate for gelatinase B/MMP-9 in vivo. Cell (2000) 102 (In Press).
  • SUZUKI M, RAAB G, MOSES MA, FERNANDEZ CA, KLAGSBRUN M: Matrix met alloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific jux tamembrane site. J Biol. Chem. (1997) 272(50):31730–31737.
  • PATTERSON BC, SANG QXA: Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagen ase (MMP-9).j Biol. Chem. (1997) 272 (46):28823–28825.
  • LEVI E, FRIDMAN R, MIAO HQ et al.: Matrix met allopro-teinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc. Natl. Acad. ScL USA (1996) 93(107069–7074.
  • FOWLKES JL, ENGHILD JJ, SUZUKI K, NAGASE H: Matrix met alloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J. Biol. Chem. (1994) 269(40:25742–25746.
  • THOMASSET N, LOCHTER A, SYMPSON CJ et al: Expres-sion of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. Am. J. Pathol. (1998) 153 (2):457–467.
  • TLSTY TD: Cell-adhesion-dependent influences on gen o m ic instability and car cin o gen esis Cum Opin. Cell Biol. (1998) 10(5):647–653.
  • KATAOKA H, UCHINO H, IWAMURA T et al: Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of a-proteinase inhibitor generated by matrix met alloproteinases: a possible modulatory role in natural killer cytotoxicity. Am. J Pathol (1999) 154 (2):457–468.
  • MCQUIBBAN GA, GONG JH, TAM EM et al.: Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science (2000) 289 (5482):1202–1206.
  • •The first use of a yeast two-hybrid system to identify an MMP substrate.
  • ALEXANDER CM, HOWARD EW, BISSELL MJ, WERB Z: Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of met alloproteinases-1 transgene. J Cell Biol. (1996) 135(6 Pt 0:1669–1677.
  • POWELL WC, FINGLETON B, WILSON CL, BOOTHBY M, MATRISIAN LM: The met alloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr. Biol. (1999) 9(201441–1447.
  • •The first study to show that an MMP can induce the Fas-mediated apoptotic pathway.
  • ARENAS-HUERTERO FJ, HERRERA-GOEPFERT R, DELGADO-CHAVEZ R et al.: Matrix met alloproteinases expressed in squamous cell carcinoma of the oral cavity: correlation with clinicopathologic features and neo-adjuvant chemotherapy response. J. Exp. Clin. Cancer Res. (1999) 18(3):279–284.
  • DUB, WANG P, GUO X: Expression of membrane Type1-matrix met alloproteinase in laryngeal carcinoma. Pathol. Oncol. Res. (1999) 5(3):214–217.
  • OBERG A, HOYHTYA M, TAVELIN B, STENLING R, LINDMARK G: limited value of preoperative serum analyses of matrix met alloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix met alloprote-inases (TIMP-1, TIMP-2) in colorectal cancer. AntiCancer Res. (2000) 20 (2B):1085–1091.
  • HANEMAAIJER R, VERHEIJEN JH, MAGUIRE TM et al.: Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Intl Cancer (2000) 86 (2):204–207.
  • NAKANISHI K, KAWAI T, SATO H et al.: Expression ofmatrix met alloproteinase-2 (MMP-2) and of membrane-type-l-matrix met alloproteinase (MT1-MMP) in transitional cell carcinoma of the upper urinary tract. Hum. Pathol (2000) 31(2):193–200.
  • ARA T, FUKUZAWA M, KUSAFUKA T et al: Irnmunohisto-ch emical expression of MMP-2, MMP-9 and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome. J. Pediatr. Surg. (1998) 33 (8):1272–1278.
  • BANDO E, YONEMURA Y, ENDOU Y et al.: Irnmunohisto-chemical study of MT-MMP tissue status in gastric carcinoma and correlation with survival analyzed by univariate and multivariate analysis. Oncol. Rep. (1998) 5 (6):1483–1488.
  • ETOH T, INOUE H, YOSHIKAWA Y et al.: Increasedexpression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressive-ness. Gut (2000) 47(0:50–56.
  • ITO T, ITO M, SHIOZAWA J et al.: Expression of theMMP-1 in human pancreatic carcinoma: relationship with prognostic factor. Mod. Pathol. (1999) 12(7):669–674.
  • MAATTA M, SOINI Y, LIAKKA A, AUTIO-HARMAINEN H:Differential expression of matrix met alloproteinase (MMP)-2, MMP-9 and membrane Type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin. Cancer Res. (2000) 6 (7):2726–2734.
  • MOSER PL, KIEBACK DG, HEFLER L et al.: Irnmunohisto-chemical detection of matrix met alloproteinases (MMP) 1 and 2 and tissue inhibitor of met alloprote-inase 2 (TIMP 2) in stage IB cervical cancer. AntiCancer Res. (1999) 19(50:4391–4393.
  • TALVENSAARI-MATTILA A, PAAKKO P, TURPEENNIEMI-HUJANEN T: MMP-2 positivity and age less than 40 years increases the risk for recurrence in premeno-pausal patients with node-positive breast carcinoma. Breast Cancer Res. Treat. (1999) 58(3):287–293.
  • VAISANEN A, KALLIOINEN M, TASKINEN PJ, TURPEENNIEMI-HUJANEN T: Prognostic value of MMP-2 immunoreactive protein (72 kD Type W collagenase) in primary skin melanoma. J. Pathol. (1998) 186 (1):51–58.
  • YAMASHITA K, MORI M, SHIRAISHI T, SHIBUTA K, SUGIMACHI K: Clinical significance of matrix met alloproteinase-7 expression in esophageal carcinoma. Clin. Cancer Res. (2000) 6 (3) :1169–1174.
  • ARA T, KUSAFUKA T, INOUE M et al: Determination ofimbalance between 1'vLMP-2 and TIMP-2 in human neuroblastoma by reverse-transcription polymerase chain reaction and its correlation with tumor progres-sion. J. Pediatr. Surg. (2000) 35(3):432–437.
  • GOHJI K, FUJIMOTO N, OHKAWA J, FUJII A, NAKAJIMA M:Imbalance between serum matrix met alloproteinase-2 and its inhibitor as a predictor of recurrence of urothe-lial cancer. Br. J. Cancer (1998) 77 (4):650–655.
  • CAENAZZO C, ONISTO M, SARTOR L et al: Augmentedmembrane Type 1 matrix met alloproteinase (MT1-MMP):MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis. an. Cancer Res. (1998) 4(9):2179–2186.
  • SAKAKIBARA M, KOIZUMI S, SAIKAWA Y et al.: Membrane-type matrix met alloproteinase-1 expres-sion and activation of gelatinase A as prognostic markers in advanced pediatric neuroblastoma. Cancer (1999) 85(1):231–239.
  • KUITTINEN O, SAVOLAINEN ER, KOISTINEN P, TURPEENNIEMI-HUJANEN T: Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML. AntiCancer Res. (1999) 19 (5C):4395–4400.
  • KANAYAMA H, YOKOTA K, KUROKAWA Y et al.: Prognostic values of matrix met alloproteinase-2 and tissue inhibitor of met alloproteinase-2 expression in bladder cancer. Cancer (1998) 82 (7):1359–1366.
  • TALVENSAARI A, APAJA-SARKKINEN M, HOYHTYA M et al.: Matrix met alloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferen-tiation. Gynecol. Oncol. (1999) 7 2 (3) :306–311.
  • CHENARD MP, O'SIORAIN L, SHERING S et al.: High levelsof stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int. J. Cancer (1996) 69 (6):448–451.
  • AHMAD A, HANBY A, DUBLIN E et al.: Str omely sin 3: anindependent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expres-sion. Am. J. Pathol. (1998) 152(3):721–728.
  • DAVIDSON B, GOLDBERG I, KOPOLOVIC J et al: MMP-2and TIMP-2 expression correlates with poor prognosis in cervical carcinoma-a clinicopathologic study using immunohistochemistry and mRNA in situ hybridiza-tion. Gynecol Oncol. (1999) 73(3):372–382.
  • NUOVO GJ, MACCONNELL PB, SIMSIR A, VALEA F, FRENCH DL: Correlation of the in situ detection of polymerase chain reaction-amplified met alloprote-inase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res. (1996) 55 (2):267–275.
  • SCULLY SP, BEREND KR, QI WN, HARRELSON JM: Collage-nase specificity in chondrosarcoma metastasis. Braz. Med. Biol. Res. (1999) 32 (7):885–889.
  • MURRAY GI, DUNCAN ME, O'NEIL P, MELVIN WT, FOTHERGILL JE: Matrix met alloproteinase-1 is associ-ated with poor prognosis in colorectal cancer. Nature Med. (1996) 2(4):461–462.
  • ZENG ZS, HUANG Y, COHEN AM, GUILLEM JG: Predic-tion of colorectal cancer relapse and survival via tissue RNA levels of matrix met alloproteinase-9. j Clin. Oncol. (1996) 1 4 (12):3133–3140.
  • SUNAMI E, TSUNO N, OSADA T et al.: MMP-1 is aprognostic marker for hematogenous metastasis of colorectal cancer. Oncologist (2000) 5 (2) :108–114.
  • MURRAY GI, DUNCAN ME, O'NEIL P et al.: Matrixmet alloproteinase-1 is associated with poor prognosis in oesophageal cancer. J. Pathol (1998) 185 (3):256–261.
  • INOUE T, YASHIRO M, NISHIMURA S et al.: Matrix met alloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int. J. Mot. Med. (1999) 4(0:73–77.
  • ALLGAYER H, BABIC R, BEYER BC et al.: Prognostic relevance of MMP-2 (72-kD collagen ase IV) in gastric cancer. Oncology (1998) 55(2):152–160.
  • MORI M, MIMORI K, SHIRAISHI T et al.: Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int. J. Cancer (1997) 74(3):316–321.
  • GRIGIONI WF, D'ERRICO A, FORTUNATO C et al.: Prognosis of gastric carcinoma revealed by interac-tions between tumor cells and basement membrane. Mod. Pathol (1994) 7(2):220–225.
  • MICHAEL M, BABIC B, KHOKHA R et al: Expression andprognostic significance of met alloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J. Clin. Oncol. (1999) 17(6):1802–1808.
  • HERBST RS, YANO S, KUNIYASU H et al.: Differentialexpression of E-cadherin and Type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. an. Cancer Res. (2000) 6 (3):790–797.
  • YLISIRNIO S, HOYHTYA M, TURPEENNIEMI-HUJANEN T: Serum matrix met alloproteinases-2, -9 and tissue inhibitors of met alloproteinases-1, -2 in lung cancer-TIMP-1 as a prognostic marker. AntiCancer Res. (2000) 20(2B):1311–1316.
  • KODATE M, KASAI T, HASHIMOTO H et al: Expression of matrix met alloproteinase (gelatinase) in Ti adenocar-cinoma of the lung. Pathol. Int. (1997) 47(7):461–469.
  • VAISANEN A, KALLIOINEN M, VON DICKHOFF K et al.: Matrix met alloproteinase-2 (MMP-2) immunoreactive protein-a new prognostic marker in uveal melanoma? Pathol. (1999) 188(0:56–62.
  • MIYAJIMA Y, NAKANO R, MORIMATSU M: Analysis of expression of matrix met alloproteinases-2 and-9 in hypopharyngeal squamous cell carcinoma by in situ hybridization. Ann. Otol. Rhino]. Laryngol. (1995) 104(9 Pt 0:678–684.
  • KUSUKAWA J, SASAGURI Y, MORIMATSU M, KAMEYAMAT: Expression of matrix met alloproteinase-3 in stage I and II squamous cell carcinoma of the oral cavity. J. Oral Maxillofac. Surg. (1995) 53(5):530–534.
  • WESTERLUND A, APAJA-SARKKINEN M, HOYHTYA M, PUISTOLA U, TURPEENNIEMI-HUJANEN T: Gelatinase A-immunoreactive protein in ovarian lesions-prognostic value in epithelial ovarian cancer. Gynecol. Oncol. (1999) 75(0:91–98.
  • GARZETTI GG, CIAVATTINI A, LUCARINI G et al.: Tissueand serum met alloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. AntiCancer Res. (1995) 15 (6B):2799–2804.
  • KUNIYASU H, ELLIS LM, EVANS DB et al.: Relative expres-sion of E-cadherin and Type IV collagenase genes predicts disease outcome in patients with respectable pancreatic carcinoma. Clin. Cancer Res. (1999) 5 (1):25–33.
  • KOSHIBA T, HOSOTANI R, WADA M et al.: Involvementof matrix met alloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer (1998) 82 (4):642–650.
  • BARCELLOS-HOFF MH, RAVANI SA: Irradiatedmammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. (2000) 60 (5) :1254–1260.
  • MOINFAR F, MAN YG, ARNOULD L et al.: Concurrent andindependent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res. (2000) 60 (9):2562–2566.
  • KINZLER KW, VOGELSTEIN B: landscaping the cancerterrain [comment]. Science (1998) 280 (5366):1036–1037.
  • WILLENBUCHER RF, AUST DE, CHANG CG et al.: Genomicinstability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am. J. Pathol. (1999) 154(6):1825–1830.
  • MEHINDATE K, AL-DACCAK R, AOUDJIT F et al.: Interleukin-4, transforming growth factor beta 1 and dexamethasone inhibit superantigen-induced prosta-glandin F2-dependent collagenase gene expression through their action on cyclooxygenase-2 and cytosolic phospholipase A2. Lab. Invest. (1996) 75 (4) :529–538.
  • BUCK TB, YOSHIJI H, HARRIS SR, BUNCE OR, THORGEIRSSON UP: The effects of sustained elevated levels of circulating tissue inhibitor of met alloproteinases-1 on the development of breast cancer in mice. Ann. NY Acad. Sci. (1999) 878:732–735.
  • RUDOLPH-OWEN LA, CANNON P, MATRISIAN LM: Overexpression of the matrix met alloproteinase matrilysin results in premature mammary gland differentiation and male infertility. Mol. Biol. Cell (1998) 9(2)421–435.
  • COUSSENS LM, TINKLE CL, HANAHAN D, WERB Z: Inflammatory cell-derived gelatinase B/MMP-9 regulates proliferation, angiogenesis and malignancy during squamous carcin o gen esis. Cell (2000) (In Press).
  • ••The first study showing that the absence of MMP9 can selectfor less differentiated cancers.
  • MATRISIAN LM: Cancer biology: ex tracellular proteinases in malignancy. Curr. Biol. (1999) 9 (20):R776–778.
  • WITTY JP, WRIGHT JH, MATRISIAN LM: Matrix met allo-proteinases are expressed during ductal and alveolar mammary morphogenesis and misregulation of stromelysin-1 in transgenic mice induces unsched-uled alveolar development. Moi Biol. Cell (1995) 6(10):1287–1303.
  • HEPPNER-GOSS KJ, BROWN PD, MATRISISAN LM: Differing effects of endogenous and synthetic inhibi-tors of met alloproteinases on intestinal tumorige-nesis. Int. J. Cancer (1998) 78:629–635.
  • HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumori-genesis. Cell (1996) 86(3):353–364.
  • BERGERS G, BREKKEN R, MCMAHON J et al.: Gelatinase B/MMP-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. (2000) 2:737–744.
  • ••An important study indicating that gelatinases cancontribute to angiogenesis and tumour progression in a stage-dependent manner.
  • ITOH T, TANIOKA M, YOSHIDA H et al.: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. (1998) 58:1048–1051.
  • ••An interesting study indicating the importance of MMP2 inangiogenesis and hematogenous metastasis.
  • FANG J, SHING Y, WIEDERSCHAIN D et al.: Matrix met alloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Nati Acad. Sci. USA (2000) 97 (8):3884–3889.
  • YU Q, STAMENKOVIC I: Cell surface-localized matrix met alloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. (2000) 14(2):163–176.
  • BROOKS PC, SILLETTI S, VON SCHALSCHA TL, FRIEDLANDER M, CHERESH DA: Disruption of angiogenesis by PEX, a noncatalytic met alloproteinase fragment with integrin binding activity. Cell (1998) 92(3)391–400.
  • ••The first study showing that the MMP hemopexin domaincan act as an angiogenesis inhibitor.
  • O'REILLY MS, HOLMGREN L, SHING Y et al.: A novel angiogenesis inhibitor which mediates the suppres-sion of metastasis by a Lewis lung carcinoma. Cell (1994) 79:315–328.
  • ••The first study showing that an extracellular proteinfragment can have anti-angiogenic activity.
  • DONG Z, KUMAR R, YANG X, FIDLER IJ: Macrophage-derived met alloelastase is responsible for the genera-tion of angiostatin in Lewis lung carcinoma. Cell (1997) 88 (6):801–810.
  • O'REILLY MS, WIEDERSCHAIN D, STETLER-STEVENSON WG, FOLKMAN J, MOSES MA: Regulation of angiostatin production by matrix met alloproteinase-2 in a model of concomitant resistance. J. Biol. Chem. (1999) 274 (40:29568–29571.
  • O'REILLY MS, BOEHM T, SHING Y et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88(2):277–285.
  • STETLER-STEVENSON WG, HEWITT R, CORCORAN M: Matrix met alloproteinases and tumor invasion: from correlation and causality to the clinic. Semin. Cancer Biol. (1996) 7(3):147–154.
  • COMPAGNI A, CHRISTOFORI G: Recent advances in research on multistage tumorigenesis. Br. J Cancer (2000) 83(1):1–5.
  • PERL AK, WILGENBUS P, DAHL U, SEMB H, CHRISTOFORI G: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature (1998) 392 (6672):190–193.
  • ••An important study indicating the tumour suppressiveeffects of E-cadherin.
  • YONEDA T, SASAKI A, DUNSTAN C et al.: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the biphosphonate ibandronate and tissue inhibitor of the matrix-met alloproteinase-2. J. C/in. Invest. (1997) 99(102509–2517.
  • KIM J, YU W, KOVALSKI K, OSSOWSKI L: Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell (1998) 94(3):353–362.
  • ••An important study suggesting that MMPs play an importantrole in tumour cell intravasation.
  • KOOP S, KHOKHA R, SCHMIDT EE et al.: Overexpression of met alloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res. (1994) 54(17):4791–4797.
  • ••The first study to suggest that MMPs influence metastaticgrowth rather than extravasation.
  • MURPHY G, WILLENBROCK F: Tissue inhibitors of matrix met alloendopeptidases. Methods Enzymol. (1995) 248:496–510.
  • BODDEN MK, HARBER GJ, BIRKEDAL-HANSEN B et al: Functional domains of human TIMP-1 (tissue inhibitor of met alloproteinases). J. Biol. Chem. (19 9 4) 2 69 (29) :18943–18952.
  • WILLIAMSON RA, CARR MD, FRENKIEL TA, FEENEY J, FREEDMAN RB: Mapping the binding site for matrix met alloproteinase on the N-terminal domain of the tissue inhibitor of met alloproteinases-2 by NMR chemical shift perturbation. Biochemistry (1997) 36 (45):13882–13889.
  • GOMIS-RUTH FX, MASKOS K, BETZ M et al.: Mechanism of inhibition of the human matrix met alloproteinase stromelysin-1 by TIMP-1. Nature (1997) 389 (6646):77–81.
  • MOTT JD, THOMAS CL, ROSENBACH MT et al.: Post-translational proteolytic processing of procol-lagen C-terminal proteinase enhancer releases a met alloproteinase inhibitor. J. Biol. Chem. (2000) 275 (2):1384–1390.
  • KHOKHA R, WATERHOUSE P, YAGEL S et al: Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science (1989) 243 (4893):947–950.
  • ••The first study showing that MMPs may participate intumour initiating events.
  • SHOJI A, SAKAMOTO Y, TSUCHIYA T et al.: Inhibition of tumor promoter activity toward mouse fibroblasts and their in vitro transformation by tissue inhibitor of met alloproteinases-1 (TIMP-1). Carcinogenesis (1997) 18(10:2093–2100.
  • KHOKHA R: Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivoby the overexpression of the tissue inhibitor of met alloproteinases-1. J. Natl. Cancer Inst. (1994) 86 (4):299–304.
  • KRUGER A, FATA JE, KHOKHA R: Altered tumor growth and metastasis of a T-cell lymphoma in TIMP-1 transgenic mice. Blood (1997) 90 (5):1993–2000.
  • CHESLER L, GOLDE DW, BERSCH N, JOHNSON MD: M et alloproteinase inhibition and erythroid potentia-tion are independent activities of tissue inhibitor of met alloproteinases-1. Blood (1995) 86 (12):4506–4515.
  • DOCHERTY AJ, LYONS A, SMITH BJ et al.: Sequence of human tissue inhibitor of met alloproteinases and its identity to erythroid-p o ten tiating activity. Nature (1985) 318(6041):66–69.
  • BERTAUX B, HORNEBECK W, EISEN AZ, DUBERTRET L: Growth stimulation of human keratinocytes by tissue inhibitor of met alloproteinases. j Invest. Dermatol. (1991) 97 (0679–685.
  • YOSHIJI H, HARRIS SR, RASO E et al.: Mammary carcinoma cells over-expressing tissue inhibitor of met alloproteinases-1 show enhanced vascular endothelial growth factor expression. Int. J Cancer (1998) 75(0:81–87.
  • GUEDEZ L, COURTEMANCH L, STETLER-STEVENSON M: Tissue inhibitor of met alloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood (1998) 92(01342–1349.
  • GUEDEZ L, STETLER-STEVENSON WG, WOLFF L et al.: In vitro suppression of programmed cell death of B cells by tissue inhibitor of met alloproteinases-1. j Clin. Invest. (1998) 102(10:2002–2010.
  • BAKER T, TICKLES, WASAN H et al.: Serum met alloprote-inases and their inhibitors: markers for malignant potential. Br. J. Cancer (1994) 70:506-512.
  • KOSSAKOWSKA AE, HUCHCROFT SA, URBANSKI SJ, EDWARDS DR: Comparative analysis of the expression patterns of met alloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br. J. Cancer (1996) 73(10:1401–1408.
  • LINDSAY CK, THORGEIRSSON UP, TSUDA H, HIROHASHI S: Expression of tissue inhibitor of met alloproteinase-1 and Type W collagenase/gelati-nase messenger RNAs in human breast cancer. Human Pathol. (1997) 2 8 (3):359–366.
  • YOSHIJI H, GOMEZ DE, THORGEIRSSON UP: Enhanced RNA expression of tissue inhibitor of met alloproteinases-1 (TIMP-1) in human breast cancer. Int. J. Cancer (1996) 69(2):131–134.
  • ZENG ZS, COHEN AM, ZHANG ZF, STETLER-STEVENSON W, GUILLEM JG: Elevated tissue inhibitor of met allo-proteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin. Cancer Res. (1995) 1(8):899–906.
  • JUNG K, NOWAK L, LEIN M et al: Matrix met alloprote-inases 1 and 3, tissue inhibitor of met alloproteinase-1 and the complex of met alloproteinase-1 /tissue inhibitor in plasma of patients with prostate cancer. Int. J. Cancer (1997) 74(2):220–223.
  • REE AH, FLORENES VA, BERG JP et al: High levels of messenger RNAs for tissue inhibitors of met alloprote-inases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin. Cancer Res. (1 9 9 7) 3 (9) :1623-1628.
  • MIMORI K, MORI M, SHIRAISHI T et al: Clinical signifi-cance of tissue inhibitor of met alloproteinase expres-sion in gastric carcinoma. Br. J. Cancer (1997) 76 (4):531–536.
  • MCCARTHY K, MAGUIRE T, MCGREAL G et al.: High levels of tissue inhibitor of met alloproteinase-1 predict poor outcome in patients with breast cancer. Int. J. Cancer (1999) 84(1):44–48.
  • NARUO S, KANAYAMA H, AKI M, KAGAWA S: Gene expressions of Type IV collagenase and tissue inhibitor of met alloproteinases (TIMP) in human bladder cancers. Nippon Hinyokika Gakkai Zasshi (1993) 84 (5):841–850.
  • STETLER-STEVENSON WG, BERSCH N, GOLDE DW: Tissue inhibitor of met alloproteinase-2 (TIMP-2) has erythroid-p o ten tiating activity. FEBS Lett. (1992) 296 (2):231–234.
  • HAYAKAWA T, YAMASHITA K, OHUCHI E, SHINAGAWA A: Cell growth-promoting activity of tissue inhibitor of met alloproteinases-2 (TIMP-2). J. Cell Science (1994) 107 (Pt 9) (3):2373–2379.
  • NEMETH JA, RAFE A, STEINER M, GOOLSBY CL: TIMP-2 growth-stimulatory activity: a concentration-and cell type-specific response in the presence of insulin. Exp. Cell Res. (1996) 224 (0:110–115.
  • IMREN S, KOHN DB, SHIMADA H, BLAVIER L, DECLERCK YA: Overexpression of tissue inhibitor of met alloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res. (1996) 5 6 (13):2891–2895.
  • ARII S, MISE M, HARADA T et al.: Overexpression of matrix met alloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology (1996) 24 (2):316–322.
  • STETLER-STEVENSON WG, BROWN PD, ONISTO M, LEVY AT, LIOTTA LA: Tissue inhibitor of met alloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. j Biol. Chem. (1990) 265 (23) :13933–13938.
  • MOSER PL, HEFLER L, TEMPFER C et al.: Irnmunohisto-chemical detection of matrix met alloproteinases (MMP) 1 and 2 and tissue inhibitor of met alloprote-inase 2 (TIMP 2) in stage I and II endometrial cancer. AntiCancer Res. (1999) 19 (3B):2365–2367.
  • KURAHARA S, SHINOHARA M, IKEBE T et al: Expression of MMPS, MT-MMP and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck (1999) 21 (7):627–638.
  • RING P, JOHANSSON K, HOYHTYA M, RUBIN K, LINDMARK G: Expression of tissue inhibitor o f met allo-proteinases TIMP-2 in human colorectal cancer-a predictor of tumour stage. Br. J. Cancer (1997) 76 (6):805–811.
  • BEAULIEU E, KACHRA Z, MOUSSEAU N et al.: Matrix met alloproteinases and their inhibitors in human pituitary tumors. Neurosurgery (1999) 45(6):1432–1440; discussion 1440–1431.
  • THOMAS P, KHOKHA R, SHEPHERD FA, FELD R, TSAO MS: Differential expression of matrix met alloproteinases and their inhibitors in non-small cell lung cancer. J. Pathol. (2000) 1 9 0 (2) :150–156.
  • STASKUS PW, MASIARZ FR, PALLANCK LJ, HAWKES SP: The 21-kDa protein is a transformation-sensitive met alloproteinase inhibitor of chicken fibroblasts. J. Biol. Chem. (1991) 266(0:449–454.
  • LU XQ, LEVY M, WEINSTEIN IB, SANTELLA RM: Immuno-logical quantitation of levels of tissue inhibitor of met alloproteinase-1 in human colon cancer. Cancer Res. (1991) 51(23 Pt 0:6231–6235.
  • UR1A JA, FERRANDO AA, VELASCO G, FREIJE JM, LOPEZ-OTIN Structure and expression in breast tumors of human TIMP-3, a new member of the met alloprote-inase inhibitor family. Cancer Res. (1994) 54 (6):2091–2094.
  • BACHMAN KE, HERMAN JG, CORN PG et al.: Methylation-associated silencing of the tissue inhibitor of met alloproteinase-3 gene suggests a suppressor role in kidney, brain and other human cancers. Cancer Res. (1999) 5 9 (4):798–802.
  • AMOUR A, SLOCOMBE PM, WEBSTER A et al.: TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. (1998) 435(0:39–44.
  • WANG M, LIU YE, GREENE J et al.: Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of met alloproteinase 4. Oncogene (1997) 1 4 (23):2767–2774.
  • UITTO VJ, FIRTH JD, NIP L, GOLUB LM: Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratino-cytes. Ann. NY Acad. Sci. (1994) 732:140–151.
  • JOHNSON LL, DYER R, HUPE DJ: Matrix met alloprote-inases. Curr. Opin. Chem. Biol. (1998) 2:466–471.
  • DRUMMOND AH, BECKETT P, BROWN PD et al.: Preclinical and clinical studies of MMP inhibitors in cancer. Ann. NY Acad. Sci. (1999) 878:228–235.
  • SHALINSKY DR, BREKKEN J, ZOU H et al.: Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. NY Acad. Sci. (1999) 878:236–270.
  • •An excellent review of the development and testing of AG3340.
  • ADAMS JM, CORY S: Transgenic models of tumor development. Science (1991) 254 (5035):1161–1167.
  • HURSTING SD: Experimental models of gene-environment interaction for cancer chemopre-vention studies. Curr. Opin. Oncol. (1997) 9(5):487–491.
  • BROWN PD: Synthetic inhibitors of matrix met allopro-teinases. In: Matrix M et alloproteinases. Parks WC, Mecham RP (Eds.), Academic Press, San Diego (1998):243–261.
  • •An excellent overall review of MMPI development.
  • BROWN PD, GIAVAZZI R: Matrix met alloproteinase inhibition: a review of anti-tumour activity. Ann. Oncol. (1995) 6(10):967–974.
  • MCCAWLEY LJ, MATRISIAN LM: Matrix met alloprote-inases: multifunctional contributors to tumor progres-sion. Mol. Med. Today (2000) 6(4):149–156.
  • ••An excellent review of the role of MMPs and MMPIs incancer.
  • SHALINSKY DR, SHETTY B, PITHAVALA Y et al.: Prinomastat: a potent and selective matrix met allopro-teinase inhibitor-preclinical and clinical develop-ment for oncology. In: Matrix M et alloproteinase Inhibitors in Cancer Therapy Clendeninn NJ, Appelt K (Eds.), Humana Press, Totowa, New Jersey, USA (2000):143–173.
  • HAQ M, SHAFII A, ZERVOS EE, ROSEMURGY AS: Addition of matrix met alloproteinase inhibition to conven-tional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. Cancer Res. (2000) 60 (12):3207–3211.
  • PRONTERA C, MARIANI B, ROSSI C, POGGI A, ROTILIO D: Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Izwis lung carcinoma. Int. J. Cancer (1999) 81:761–766.
  • SHALINSKY DR, BREKKEN J, ZOU H et al: Marked an tiangiogenic and antitumor efficacy of AG3340in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clin. Cancer Res. (1999) 5 (7):1905–1907.
  • SHI Z, RAITHATHA S, SPENCER D et al: Enhanced effectiveness of a novel MMP inhibitor, prinomastat (AG3340) with radiation therapy (RI) in aglioma model. Proc. Am. Assoc. Cancer Res. (2000) 41:326 (A2071).
  • BURKE F, EAST N, UPTON C, PATEL K, BALKWILL FR: Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat. Eur. J. Cancer (1997) 33 (7):1114–1121.
  • GIAVAZZI R, GAROFALO A, FERRI C et al: Batimastat, a synthetic inhibitor of matrix met alloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin. Cancer Res. (1998) 4 (4):985–992.
  • ZOU H, BREKKEN J, FEELEY R, SHALINSKY DR: Antitumor efficacy and longterm sensitivity to prinomastat (AG3340) after extended in vivo treatment. Clin. Cancer Res. (1999) 5 (Suppl.):52.
  • KLEMENT G, BARUCHEL S, RAK J et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regres-sion without overt toxicity. J. an. Invest. (2000) 105 (8):R15–24.
  • BROWDER T, BUTTERFIELD CE, KRALING BM et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. (2000) 60 (7):1878–1886.
  • HANAHAN D, BERGERS G, BERGSLAND E: less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice [comment]. J Clin. Invest. (2000) 105 (8):1045–1047.
  • KISHI K, MILAS L, HUNTER N, SATO M: Recent studies on anti-angiogenesis in cancer therapy [in process citation]. Nippon Rinsho (2000) 58 (8):1747–1762.
  • BEATTIE GJ, SMYTH JF: Phase I study of intraperitoneal met alloproteinase inhibitor BB94 in patients with malignant ascites. Clin. Cancer Res. (1998) 4(8):1899–1902.
  • MALFETANO J, TENG N, BARTER J et al.: Marimastat in patients with advanced cancer of the ovary-a dose-finding study. Proc. Am. Soc. Clin. Oncol. (1997) 1331.
  • ZAKNOEN S, WOLFF R, COX J et al.: Marimastat in advanced progressive colorectal cancer-a dose-finding study. Proc. Am. Soc. Clin. Oncol (1997) 968.
  • ROTHENBERG ML, NELSON AR, HANDE KR: New drugs on the horizon: matrix met alloproteinase inhibitors. Stem Cells (1999) 17:237–240.
  • FIELDING J, SCHOLEFIELD R, STUART R et al.: A random-ized double-blind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinomas. Proc. Am. Soc. Clin. Oncol. (2000) 929.
  • MALCOLM J, MOORE J, HAMM J et al.: A comparison between gemcitabine (GEM) and the matrix met allo-proteinase (MMP) inhibitor BAY12-9566 (9566) in patients (PTS) with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol (2000) 930.
  • TOLCHER A, ROWINSKY EK, RIZZO J et al: A Phase land pharmacokinetic study of the oral matrix met allopro-teinase inhibitor Bay12-9566 in combination with paclitaxel and carboplatin. Proc. Am. Soc. Clin. Oncol. (1999) 617.
  • COLLIER M, SHEPHERD F, AHMANN FR et al.: A novel approach to studying the efficacy of AG3340, a selective inhibitor of matrix met alloproteases (MMPs). Proc. Am. Soc. Clin. Oncol (1999) 1861.
  • WILDING G, SMALL E, COLLIER M, DIXON M, PITHAVALA Y: A Phase I pharmacokinetic evaluation of matrix met alloprotease (MMP) inhibitor AG3340 in combina-tion with mitoxantrone and prednisone in patients with advanced prostate cancer. Proc. Am. Soc. Clin. Oncol. (1999) 1244.
  • D'OLIMPIO J, HANDE K, COLLIER M et al.: Phase I study of the matrix met alloprotease inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol (1999) 615.

Websites

  • http://www.people.Virginia.EDU/%7Ejag6n/ Table_of the_ADAMs.html JM White. Table of the ADAMS.
  • http://www.lerner.ccf.org/bme/staff/apte/adamts SS Apte. The Apte Lab ADAMTS and ADAMTSL Resource.
  • http://cancertrials.nci.nih.gov/news/angio/angiomore.html Cancer Trials. A service of the National Cancer Institute.
  • http://britbio.co.uk/britishbiotech/news/128.txt British Biotech news release (15 Feb 1999).
  • http://britbio.co.uk/britishbiotech/news/193_results.txt British Biotech news release (25 Jan 2000).
  • http://www.bayerpharma-na.com/clinicaltrials/default.asp Clinical Trials at Bayer (24 Sept 1999).
  • http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=105 &STORY4www/story/08-04-2000/0001283340 Pfizer press release (4 Aug 2000).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.